CASE REPORT

Prolidase deficiency, a rare inborn error of immunity, clinical phenotypes, immunological features, and proposed treatments in twins

Nora Alrumayyan1, Drew Slauenwhite1, Sarah M. McAlpine1, Sarah Roberts1, Thomas B. Issekutz1, Adam M. Huber2, Zaiping Liu3 and Beata Derfalvi1*

Abstract

Background: Prolidase deficiency (PD) is an autosomal recessive inborn multisystemic disease caused by mutations in the PEPD gene encoding the enzyme prolidase D, leading to defects in turnover of proline-containing proteins, such as collagen. PD is categorized as a metabolic disease, but also as an inborn error of immunity. PD presents with a range of findings including dysmorphic features, intellectual disabilities, recurrent infections, intractable skin ulceration, autoimmunity, and splenomegaly. Despite symptoms of immune dysregulation, only very limited immunologic assessments have been reported and standard therapies for PD have not been described. We report twin females with PD, including comprehensive immunologic profiles and treatment modalities used.

Case presentation: Patient 1 had recurrent infections in childhood. At age 13, she presented with telangiectasia, followed by painful, refractory skin ulcerations on her lower limbs, where skin biopsy excluded vasculitis. She had typical dysmorphic features of PD. Next-generation sequencing revealed pathogenic compound heterozygous mutations (premature stop codons) in the PEPD gene. Patient 2 had the same mutations, typical PD facial features, atopy, and telangiectasias, but no skin ulceration. Both patients had imidodipeptiduria. Lymphocyte subset analysis revealed low-normal frequency of T reg cells and decreased frequency of expression of the checkpoint molecule CTLA-4 in CD4+ TEM cells. Analysis of Th1, Th2, and Th17 profiles revealed increased inflammatory IL-17+ CD8+ TEM cells in both patients and overexpression of the activation marker HLA-DR on CD4+ TEM cells, reflecting a highly activated proinflammatory state. Neither PD patient had specific antibody deficiencies despite low CD4+CXCR5+ Tfh cells and low class-switched memory B cells. Plasma IL-18 levels were exceptionally high.

Conclusions: Immunologic abnormalities including skewed frequencies of activated inflammatory CD4+ and CD8+ TEM cells, decreased CTLA-4 expression, and defects in memory B cells may be a feature of immune dysregulation associated with PD; however, a larger sample size is required to validate these findings. The high IL-18 plasma levels suggest underlying autoinflammatory processes.

Keywords: Prolidase deficiency, T cells, Inborn error of immunity, Autoimmunity, Leg ulcers

*Correspondence: beata.derfalvi@iwk.nshealth.ca
1 Division of Immunology, Department of Paediatrics, Dalhousie University, IWK Health Centre, Halifax, Canada
Full list of author information is available at the end of the article
prolidase D, leading to defects in turnover of collagen and other proline-containing proteins. Since it was first described in 1968 by Goodman [1], 35 causative mutant alleles have been reported in the ninety cases worldwide [2, 3]. The incidence of PD is estimated to be 1–2 per million births, but it is more frequent in some populations, including the Druze and Arab Muslim minorities in Israel [2–6]. PD is categorized under Diseases of Immune Dysregulation, Syndromes with Autoimmunity in the 2019 IUIS Phenotypical Classification of Human Inborn Errors of Immunity [7]. PD is often referred to as a “lupus mimic”, presenting predominantly with cutaneous features and with systemic autoimmunity [8–12]. Typical presentation of PD includes intractable skin ulceration, telangiectasia, recurrent infections, splenomegaly, dysmorphic features, and intellectual disabilities [2, 13]. Thrombocytopenia, hypocomplementemia, and hypergammaglobulinemia are frequent laboratory findings, as are increased levels of proline metabolites in serum and urine [9, 14–18].

To date, no standard diagnostic criteria or testing algorithms for PD have been published. PD is diagnosed by the detection of either biallelic PEPD pathogenic variants or reduced prolidase enzyme activity in patients who present with characteristic clinical findings and imidodipeptiduria [2, 17, 19]. The aim of this study was to identify features associated with immune dysregulation in PD patients through comprehensive immunologic assessments.

**Case presentation**

The index case, Patient 1 (Pt1), had recurrent ear and throat infections in early childhood, which when treated with antibiotics, tonsillectomy, adenoidectomy, and bilateral myringotomy tube insertion, lead to less frequent infections. At 13 years of age, Pt1 presented with severe, chronic, refractory skin ulcerations on her lower extremities, which prevented ambulation. Patient 2 (Pt2), an identical twin of Pt1, presented with recurrent respiratory tract infections as well as severe atopy, including anaphylaxis to multiple food allergens, allergic rhinitis, and asthma. Pt2 also had recurrent arthralgia, mainly in the large joints, with no stiffness or limitation of movement. No skin ulceration was present in Pt2. Both Pt1 and Pt2 presented with telangiectasia predominantly in their lower extremities. The clinical findings of both patients are summarized in Table 1.

Physical examination at 15 years of age showed that both twins had dysmorphic features, including a low hairline, mild ptosis, hypertelorism, a depressed nasal root, a beak-like nose, and micrognathia (Fig. 1). Pt1 had ulcers on the feet at different stages of healing with white discoloration (“atrophie blanche”) of the skin around the ulceration (Fig. 2). Pt1 also had splenomegaly. Musculoskeletal examination was normal in both cases, except for observed hypermobility in Pt2. A sole skin punch biopsy was performed for Pt1 and excluded vasculitis but revealed livedoid vasculopathy with perivascular lymphocytic infiltration (Fig. 3). Poor wound healing was observed as the biopsy site did not heal for one year. Pt1 was diagnosed with PD at the age of 15 following next generation sequencing of 298 primary immunodeficiency genes (Blueprint Genetics). Previously reported pathogenic compound heterozygous mutations (c.977G>A, p.Trp326* and c.550C>T; p.Arg184*), which introduced premature stop codons in the PEPD gene, were detected [20, 21]. Pt2 was found to have the same mutations. The non-consanguineous asymptomatic parents are carriers of one of the PEPD mutant variants, confirming trans position of the

**Table 1** Clinical presentation in twin females with PD

| Known clinical presentation of PD | Patient 1 | Patient 2 |
|-----------------------------------|-----------|-----------|
| Skin manifestations               | Diffuse telangiectasias Ulceration of the feet | Telangiectasia one foot ulcer after 2 years |
| Dysmorphic features               | +         | +         |
| Intellectual disability (ID)      | +         | +         |
| Recurrent infections              | +         | +         |
| Coexistence autoimmunity          | Euthyroid autoimmune thyroiditis | – |
| Allergic symptoms and atopy       | –         | +++ Bronchial asthma, allergic rhinitis, eczema, food allergy |
| Endocrinopathies                  | –         | –         |
| Pulmonary manifestations           | –         | –         |
| Splenomegaly/hepatomegaly         | ++        | –/+       |
| Other                             | –         | Arthralgia and hyper laxity |

+, clinical feature present; –, clinical feature absent
mutated alleles. Imidodipeptiduria, indicating increased proline metabolites, confirmed PD in both patients [22] (Fig. 4). Family history for immune-mediated diseases was unremarkable except for maternal psoriasis and recurrent streptococcal infections.

Pt1 required gabapentin for pain control and antidepressants to treat severe anxiety, self-harm, and depression. She was started on low-molecular-weight heparin (LMWH), pentoxifylline to improve microcirculation, and high dose (1 g/kg) intravenous immunoglobulin (IVIG) infusions for immune modulation. This resulted in the cessation of disease progression and partial healing of ulcers. After genetic diagnosis, more targeted treatments were added, including high-dose collagen synthesis cofactor vitamin C (500 mg/day), 5% proline–glycine ointment, and topical tacrolimus (0.33%). Pt1 responded well to this combined therapy initially, allowing for recovery of full physical activity, and showed no new ulceration for 4 months. All previous ulcerations closed, leaving scars and whitish discoloration. Pt1 subsequently developed one new foot ulcer, which did not impact mobility and began to heal more quickly than previous ulcers.

Pt2 was started on high dose vitamin C and pentoxifylline after presenting with white skin atrophy on the feet and mutation within PEPD was confirmed. One year later, Pt2 developed a small ulceration which was treated immediately with topical tacrolimus (0.33%) and 5% proline–glycine ointment, which stopped ulcer progression and promoted healing.
Magnetic resonance imaging (MRI) of the brain was performed for Pt1 due to chronic headaches, to rule out vasculitis, with normal results. Abdominal ultrasound showed splenomegaly in Pt1, which has been previously reported in PD [2, 3, 23], as well as hepatomegaly and diffuse hepatic steatosis in Pt1 and Pt2. The serum lipid profile revealed elevated low-density lipoprotein (LDL) and triglyceride levels in both patients, which has not been reported previously in PD. Pt1 had an overall low Wechsler Intelligence Scale for children—5th edition (IPad) (WISC-V) IQ score at the 5th percentile when tested at age 16, and she performed at the level of a 12-year-old on the vocabulary test. The WISC-V IQ score of Pt2 ranged from extremely low to low average in the various test components.

A detailed laboratory assessment was conducted including measurement of humoral immunity, three pathways of complement activation, T and B lymphocyte proliferation to mitogens and antigens, and natural killer (NK) cell cytotoxicity. Findings of laboratory investigations are detailed in Tables 2 and 3. A complete blood count showed mild thrombocytopenia in Pt1. Immunoglobulin (total IgG, IgG1-4, IgA, IgM, IgE) levels were normal with the exception of low IgG2 in Pt2. Total
Table 2  Clinical laboratory results in twin females with PD

| Test                                                                 | Patient 1          | Patient 2          | Normal range          |
|----------------------------------------------------------------------|--------------------|--------------------|-----------------------|
| **Blood cell counts**                                                |                    |                    |                       |
| White blood cells                                                    | 7.26               | 8.13               | 4.19–9.43 10e9/L      |
| Neutrophils                                                         | 2.2                | 4.22               | 1.82–7.47 10e9/L      |
| Lymphocytes                                                         | 4.09 (H)           | 2.9                | 1.16–3.33 10e9/L      |
| Monocytes                                                           | 0.73 (H)           | 0.76 (H)           | 0.19–0.72 10e9/L      |
| Platelets                                                           | 118 (L)            | 154                | 130–400 10e9/L        |
| Mean platelet volume                                                | 9.8                | 10.3               | 8–12 fl              |
| Hemoglobin                                                          | 130                | 149                | 105–150 g/L          |
| **Immunoglobulins**                                                 |                    |                    |                       |
| IgA                                                                 | 0.81               | 1.35               | 0.52–1.92 g/L        |
| IgM                                                                 | 0.63               | 1.07               | 0.47–3.11 g/L        |
| IgEb                                                                | 423                | 568                | <629 kU/L            |
| IgGc                                                                | 8.92               | 9.56               | 7–15.9 g/L          |
| IgG1                                                                | 5.77               | 7.54               | 3.15–8.55 g/L        |
| IgG2                                                                | 0.30 (L)           | 0.65               | 0.64–4.95 g/L        |
| IgG3                                                                | 0.3                | 0.29               | 0.23–1.96 g/L        |
| IgG4                                                                | 0.158              | 0.384              | 0.11–1.57 g/L        |
| **Specific antibody titers to diphtheria, tetanus, pneumococcal, rubella, varicella, and measles vaccine antigens** | Good, sustained, protective antibody titers to vaccines except borderline measles IgG response | Good, sustained, protective antibody titers to all vaccines |
| **B cell proliferation (% of CpG-stimulated cells divided)**         | 68.1%              |                    |                       |
| **T cell proliferation: mitogen and antigen stimulation of PBMCs by PHA, ConA, PWM, anti-CD3, anti-CD3 + IL-2, IL-2, tetanus toxoid, diphtheria toxoid, and Candida albicans antigens** | Normal lymphocyte proliferation to all mitogens and antigens tested | Normal lymphocyte proliferation to all mitogens and antigens tested |
| **NK cell function**                                                |                    |                    |                       |
| NK cell cytotoxicity (NK cell killing activity)                      | Normal             | Normal             |                       |
| Degranulation (CD107a+)                                              | 27%                | 22%                | 11–35%               |
| Neutrophils NBT reduction                                           | Normal oxidative burst of 99% | Normal oxidative burst of 100% |
| **Complement**                                                      |                    |                    |                       |
| CH50 classical                                                      | 93                 | 70                 | 42–96 U/mL           |
| C3p                                                                 | 1.54               | 1.63               | 1.1–1.8 g/L          |
| C4p                                                                 | 0.26               | 0.24               | 0.17–0.39 g/L        |
| MBL                                                                 | 0 (L)              | 0 (L)              | 30–200%              |
| Alternate complement                                                | 119                | 107                | >40%                 |
| **Inflammatory markers**                                            |                    |                    |                       |
| ESR                                                                 | 18 (H)             | 2                  | 0–9 mm/h             |
| CRP                                                                 | 24.6 (H)           | 6 (H)              | 0–5.0 mg/L           |
| Ferritin                                                            | 400 (H)            | 2006 (H)           | 5.5–67 mcg/L         |
| IL-18                                                               | > 36,600 (H)       | 28,803 (H)         | <266 pg/mL           |
| SAA                                                                 | 9837               | 8511               | ng/mL, within 30–70% of normal |
| **Auto-antibodies**                                                 |                    |                    | All negative         |
| ANA                                                                 | ANA IIF + (1:320, speckled pattern) | All negative |
| ENA, anti-TTG-IgA, anti-cardiolipin, anti-B2GP1, LA, ASMA, ACP, anti-LKM, anti-PR3, anti-MPO, anti-CCP, RF, anti-TPO |
| **Lipid profile**                                                   |                    |                    |                       |
| LDL                                                                 | NDg                | 3.08               | Acceptable<2.85 H>3.36 mmol/L |

Notes:
- IgE values for Patient 1 and Patient 2 are 423 and 568, respectively.
- IgG1 values for Patient 1 and Patient 2 are 5.77 and 7.54, respectively.
- IgG2 values for Patient 1 and Patient 2 are 0.30 (L) and 0.65, respectively.
- IgG3 values for Patient 1 and Patient 2 are 0.3 and 0.29, respectively.
- IgG4 values for Patient 1 and Patient 2 are 0.158 and 0.384, respectively.
- MBL values for Patient 1 and Patient 2 are 0 (L) and 0 (L), respectively.
- CRP values for Patient 1 and Patient 2 are 24.6 (H) and 6 (H), respectively.
- Ferritin values for Patient 1 and Patient 2 are 400 (H) and 2006 (H), respectively.
- IL-18 values for Patient 1 and Patient 2 are >36,600 (H) and 28,803 (H), respectively.
- SAA values for Patient 1 and Patient 2 are 9837 and 8511, respectively.
- ANA values for Patient 1 and Patient 2 are ANA IIF + (1:320, speckled pattern) and All negative, respectively.
- Lipid profile values for Patient 1 and Patient 2 are NDg and 3.08, respectively.
B cell counts were normal and antibody titers to tested vaccine antigens were sustained as protective, confirming normal specific antibody production, despite both patients having low peripheral class-switched memory B cells. Lymphocyte proliferation in response to stimulation with mitogens and antigens was normal as detected via cells. Lymphocyte proliferation in response to stimulation patients having low peripheral class-switched memory B normal specific antibody production, despite both vaccine antigens were sustained as protective, confirming B cell counts were normal and antibody titers to tested

### Table 2 (continued)

| Test      | Patient 1 | Patient 2 | Normal range       |
|-----------|-----------|-----------|-------------------|
| HDL       | 0.79 (L)  | 1.2       | Acceptable>1.17 mmol/L |
| TGA       | 6.1 (H)   | 2.21 (H)  | Acceptable<1.02 mmol/L |
| Cholesterol | 6.86 (H)  | 5.28 (H)  | Acceptable<4.40 mmol/L |

L, low; H, high; PHA, phytohemagglutinin; ConA, concanavalin A; PWM, pokeweed mitogen; NK, natural killer cells; MBL, mannose-binding lectin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SAA, serum amyloid A; PC, percentile; ANA, antinuclear antibodies; ENA, extractable nuclear antibody; SS-A/B, Sjögren’s syndrome-related antigen A/B autoantibodies; anti-TG IgA, anti-thyroglobulin IgA antibodies; anti-2BGP1, anti-beta-2-glycoprotein 1 antibodies; ASMA, anti-smooth muscle antibodies; ACPA, anti-citrullinated protein antibodies; anti-LKM, anti-liver-kidney-muscle antibodies; anti-MPO, anti-myeloperoxidase antibodies; anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; anti-TPO, anti-thyroid peroxidase antibodies; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TGA, triglycerides

- Thrombocytopenia reported in literature [1]
- Increased serum IgE levels reported in literature [2]
- Hypergammaglobulinemia reported in literature [3]
- Mean ± 2SD, n = 6 healthy donors
- Hypocomplementemia (C3 and C4) reported in literature [3]
- Positive ANA, anti-dsDNA, anti-ENA (anti-Ro), anti-Sm, and anti-chromatin have been found in individuals with prolidase deficiency even in the absence of clinical findings of SLE [2]
- Not determined due to high TGA

---

Alrumayyan et al. Allergy, Asthma & Clinical Immunology (2022) 18:17
Table 3: Absolute counts and frequencies of CD4⁺ T cell, CD8⁺ T cell, and CD4⁺ T_{reg} cell subsets in the peripheral blood of healthy controls and PD patients

| Cell type           | Subset                        | Patient 1 | Patient 2 | Normal age-related range (clinical laboratory) |
|---------------------|-------------------------------|-----------|-----------|-----------------------------------------------|
| Lymphocytes         | Absolute CD3⁺                 | 2394      | 2830      | 850–3200 cells/µL                             |
|                     | Absolute CD3⁺CD4⁺             | 1406      | 2065      | 400–2100 cells/µL                             |
|                     | Absolute CD3⁺CD8⁺             | 1178      | 766       | 300–1300 cells/µL                             |
|                     | CD4⁺/CD8⁺ ratio               | 1.1 (L)   | 2.5       | 1.5–2.5                                       |
|                     | B cells (CD19⁺)               | 122       | 266       | 120–740 cells/µL                              |
|                     | % class-switched memory B cells| 2% (L)    | 4% (L)    | 9–26%                                         |
|                     | NK cells                      | 1102      | 133       | 7–480 cells/µL                                |
|                     | CD3⁺CD4⁺CD8⁻ alpha/beta      | 0.6%      | 0.8%      | <1.5%                                         |
|                     |                               |           |           |                                               |
| CD4⁺ T cells        | CD4⁺ memory (CD45RO⁺)         | 33.1      | 19.1 (L)  | 23.4–66.5                                     |
|                     | CD4⁺ TEM                       | 21.5      | 11.4      | 9.1–48.4                                      |
|                     | CD4⁺ T_CM                     | 9.0 (H)   | 5.3       | 2.1–7.5                                       |
|                     | CD4⁺ TEMRA                    | 2.1 (L)   | 1.8 (L)   | 3.0–13.6                                      |
|                     | CD4⁺ T_eff                    | 0.3       | 0.5       | 0–2.5                                         |
|                     | CD4⁺ naïve (CD45RA⁺)          | 59.1      | 74.2 (H)  | 21.2–62.7                                     |
| CD8⁺ T cells        | CD8⁺ memory (CD45RO⁺)         | 77.3 (H)  | 39.4      | 8.2–68.3                                      |
|                     | CD8⁺ TEM                      | 30.0      | 14.7      | 0–30.7                                        |
|                     | CD8⁺ T_CM                     | 2.6 (H)   | 0.7       | 0.1–2.5                                       |
|                     | CD8⁺ TEMRA                    | 43.6 (H)  | 20.7      | 8.7–29.0                                      |
|                     | CD8⁺ T_eff                    | 2.4       | 2.5       | 0–29.4                                        |
|                     | CD8⁺ naïve (CD45RA⁺)          | 15.2      | 54.6      | 8.3–83.9                                      |
| T follicular cells  | CD4⁺ CXCR5⁺                   | 1.8 (L)   | 2.0 (L)   | 2.2–9.4                                       |
|                     | CD8⁺ CXCR5⁺                   | 0.3       | 0.2       | 0–4.4                                         |
| T_{reg} cells       | Total T_{reg} (% of CD4⁺)     | 3.6       | 2.8       | 2.6–6.3                                       |
|                     | Naive T_{reg} (CD45RO⁺)       | 27.1      | 38.9      | 15.1–49.4                                     |
|                     | Memory T_{reg} (CD45RO⁺)      | 57.2      | 41.8      | 40–82                                          |
| T cell cytokines    | CD4⁺ TEM IFN-γ⁺               | 37.5      | 9.3 (L)   | 12.8–56.4                                     |
|                     | CD4⁺ TEM IL-13⁺               | 3.0       | 6.8       | 2.3–7.0                                       |
|                     | CD4⁺ TEM IL-17⁺               | 1.8       | 2.4       | 1.0–3.2                                       |
|                     | CD8⁺ TEM IFN-γ⁺               | 55.2      | 35.5 (L)  | 42.0–100                                       |
|                     | CD8⁺ TEM IL-13⁺               | 0.7       | 0.4       | 0.2–8.1                                       |
|                     | CD8⁺ TEM IL-17⁺               | 1.7 (H)   | 1.4 (H)   | 0–0.9                                         |
| Checkpoint molecules| CD4⁺ TEM CTLA-4⁺              | 22.4 (L)  | 21.2 (L)  | 24.5–43.7**                                   |
|                     | CD4⁺ TEM PD-1⁺                | 58.5      | 44.9      | 26.6–70.3                                     |
|                     | CD4⁺ TEM TIM-3⁺               | 3.7 (H)   | 4.8 (H)   | 0.4–1.8                                       |
| Activation marker   | CD4⁺ TEM HLA-DR⁺              | 20.2 (H)  | 10.2 (H)  | 1.5–9.4                                       |
|                     | CD4⁺ TEM HLA-DR⁻              | 6.3       | 7.5       | 0–22.5                                        |

Information on the optimized antibody panels used for flow cytometry can be obtained by contacting the corresponding author. Numbers represent the percentage of cells comprising each subset or percentage of cells expressing the indicated markers.

T_{CM} central memory T cells; T_{EM} effector T cells; T_{ naïve} naive memory T cells; T_{ TEMRA} T cell re-expressing CD45RA⁺; H, higher than normal range; L, lower than normal range

*The normal range is represented by mean ± 2 × standard deviation of n = 7 healthy controls, mean age ± SD 34.3 ± 4.9 years and ** mean age ± SD 54.8 ± 10.8 years.

T_{reg} cells were defined as CD3⁺CD4⁺CD127⁻lowCD25⁰FoxP3⁻.
cytokines, including IL-1β, IL-6, IL-17A, and tumor necrosis factor (TNF), were within the normal range (15–97.5% distribution) in both patients, except for plasma IL-18 levels, which were increased more than 100-fold compared to healthy controls.

**Discussion**

Individuals with PD experience severe morbidity and early death, usually due to infection. To date, 90 patients with PD have been reported in the literature [3], and nine have passed away with infection as a leading cause. PD patients experience bacteremia, skin infections, and cellulitis, with frequent infection by influenza, *Pseudomonas aeruginosa*, and fungi, the latter of which is often *Candida albicans* and *Aspergillus* among others [14]. Decreased neutrophil chemotaxis was reported [26], however we did not assess this in this study. Pt1 and Pt2 presented with recurrent respiratory tract infections with MBL complement deficiency being a possible contributing factor. Moreover, prolidase is required for the maturation of type I IFN receptors [27]. PD patients lack PEPD activity, leading to inhibition of type I IFN receptor-dependent immune responses, which are critical for the amplification of innate immunity and the mobilization of adaptive immunity in response to infection.

CXCR5+CD4+ Tfh cells are specialized cells that provide help to B cells especially during affinity maturation which is essential for high-affinity antibody production and the development of memory B cells [28]. Laboratory measured immune abnormalities reported in the literature include elevated levels of IgG, IgA, IgM, and IgE, deficiency of the complement component C1q, and low C3 and C4 complement levels [13, 14, 26, 29]. Hypergammaglobulinaemia is likely secondary to recurrent infections or immune dysregulation [26, 29, 30]. The low proportion of Tfh cells in both patients may contribute to low class-switched memory B cells. Despite these observations, specific antibody production was intact as well as B cell proliferation to T cell-independent stimulation. It is possible that low circulating Tfh cells may not be reflective of lymph node-resident Tfh cell populations as the former have been shown to be phenotypically distinct from their counterparts in the tissue [31]. Indeed, mechanisms of immune deficiency in the patients in the present study do not appear to involve germinal center B cell responses or the development of effective humoral immunity.

Reports of immune dysregulation in PD patients have been published, including a patient with very early onset inflammatory bowel disease [32]. Additionally, association between systemic lupus erythematosus (SLE) and PD has been described [8–10, 12, 14, 25, 33] with common symptoms including anemia, thrombocytopenia, hypergammaglobulinemia, hypocomplementemia, and elevated titers of autoantibodies [2]. Pt1 had ANA positivity and anti-TPO autoantibodies. We focused on immune checkpoint molecules and cytokines expressed among effector memory T cells, since naive T cells express very low levels in both health and disease. We have observed a deficiency of CD4+ TEM CTLA-4+ cells and borderline low Treg cell frequencies. Although this was relatively modest, even partial CTLA-4 deficiency results in severe autoimmune disease such as in CTLA-4 haploinsufficiency with autoimmune infiltration (CHAI) [34]. In contrast, TIM-3 expression in CD4+ TEM cells was upregulated, which has been associated with reduced T cell inflammatory responses, and favorable long-term outcomes in multiple autoimmune diseases. T cell cytokine responses in both patients were normal with the exception of elevated proportions of IL-17+ CD8+ TEM cells [35]. Pt2, who presented with severe atopy, had low proportions of IFN-γ-producing T cells, a relationship which has been previously shown in patients with atopic disease [36]. Immune dysregulation is further evidenced by the chronically elevated CRP in Pt1 and very high IL-18 levels in both patients suggesting an autoinflammatory process, like in the *NLRC4* inflammasome-related clinical disease spectrum [37]. Prolidase cleaves di- and tripeptides at the carboxyl terminal of proline resulting in a unique ring structure that prevents proteolysis and maintains the protein’s biological activity [38, 39]. Damaged proline in PD, as endogenous danger signal, could lead to dysregulated inflammasome signaling and hyperinflammation. Another possible mechanism linking PD with dysregulated immune activity is through the nuclear factor kappa B (NFκB) transcription factor, which represents a critical network for coordinating inflammatory responses. Prolidase activity is inversely associated with NFκB activity. Intriguingly, the complexes which cooperate in the physiological activation or regulation of NFκB activity vary in their roles depending upon the cell type or signaling pathway involved [40]. This may explain the diverse outcomes observed within and between individuals lacking prolidase. In some immune cells or tissue microenvironments, regulation of NFκB-induced inflammation by prolidase is lost while in others it remains intact through a network of tightly regulated compensatory mechanisms. Additional studies are needed to improve our understanding of the biochemistry of prolidase-dependent regulation of transcription factor activity before mechanisms for immune dysregulation in PD become clear.

Both patients had an abnormal lipid profile, which was unexpected as they had a normal BMI, were on a healthy diet, and had no family history of first degree
coronary disease. Both had high cholesterol and LDL levels, hepatic steatosis, with hepatomegaly and elevated liver enzymes, which have not been previously observed in PD patients. Prolidase has been linked to lipid metabolism and may explain the hyperlipidemia findings, therefore indicating a need to monitor lipid levels in PD patients [41]. Intellectual disability has been reported in 71% of patients with PD [13]. The IQ scores reported vary from extremely low to low-average, in patients assessed by the WISC-V scale [3]. IQ scores of Pt1 and Pt2 were within the previously reported average for PD patients. The cause of intellectual disability in PD patients is not clear, but a recent study has proposed that PD may affect synaptic neurotransmission [42]. In addition, the basement membrane of the pial meninges (pBM), which is essential for brain cortical maturation, is predominantly composed of type IV collagen which would be negatively affected by PD due to disruptions in collagen metabolism [42].

Pt1 and Pt2 have a classical presentation of PD including dysmorphic facial features, intellectual disability, chronic, severe skin ulcers of the lower extremities, and telangiectasias. Pt1 presented with a more aggressive inflammatory disease with severe skin manifestations and autoimmunity, while Pt2 presented with more atopy. Different PD phenotypes between siblings have been previously reported and varying environmental factors or epigenetic modulators have been proposed as causative [5, 43, 44].

The treatment of PD is symptomatic and there is no recommended or curative regimen. Topical and systemic treatments have been used with only partial improvement reported. Most treatment strategies aim to replace prolidase or treat and stop ulcerative progression. Topical treatments include proline, growth hormone (GH), and tacrolimus [45–48]. Topical proline ointment has been reported to rapidly reduce ulcer size, especially when combined with a 5% glycerine ointment, but has not been shown to prevent new ulcers [2, 44, 47]. GH, LMWH, and collagen cofactor Vitamin C (4 g/kg) have been previously shown to accelerate wound healing but has not been shown to prevent new ulcer development [38, 46, 49]. Vitamin C and LMWH have been shown to reduce symptoms where patients had evidence of thrombosis in the cutaneous microcirculation [2, 38, 44, 49–51]. Topical tacrolimus, which is immunosuppressive and anti-inflammatory, was found to be very effective in treating ulcers without causing skin atrophy, however, did not prevent new ulcers [48]. Partially successful treatment with systemic immunosuppressive medications or frequent packed red blood cells transfusions have been also reported [13, 51]. In a previous study of a PD patient, hematopoietic stem cell transplantation (HSCT) was performed with signs of successful engraftment, however, the patient developed a severe infection and unfortunately died [52]. Besides monitoring the physical changes to determine clinical response to variable treatments, more objective methods to determine successful treatment could include measuring proline urine metabolism or erythrocyte prolidase levels [13, 51].

The limitations of this study include the use of peripheral blood mononuclear cells without paired tissue biopsies from sites such as the skin or lymph nodes where the balance of inflammatory and immunoregulatory processes may be different. Moreover, immunophenotyping of patients occurred after Pt1 was offered IVIG as disease activity was high preceding the blood sample collection date, which may have influenced the results. Immunophenotyping data were compared to a limited number of healthy controls which were not matched for age or sex, therefore a larger study is required to replicate these findings.

Conclusion

Prolidase deficiency is a complex disorder with a broad clinical spectrum of presentations and severity. PD, with its immune components, may be classified as a primary immune regulatory disorder (PIRD). Very high IL-18 plasma levels suggest underlying autoinflammatory processes and novel, targeted therapies should be investigated. We suggest monitoring lipid levels in patients with PD to explore a potential pathogenic link. The proposed combined therapy, including IVIG, LMWH, vitamin C, topical proline, and topical tacrolimus is promising, however, it requires long-term follow-up.

Abbreviations

ANA: Antinuclear antibody; anti-TPO: Anti-thyroid peroxidase; CBCd: Complete blood count and differential; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; GH: Growth hormone; HSCT: Hematopoietic stem cell transplantation; IVIG: Intravenous immunoglobulin; LMWH: Low molecular weight heparin; MBL: Mannose-binding lectin; NK: Natural killer; pBM: Basement membrane of the pial meninges; PBMC: Peripheral blood mononuclear cell; PD: Prolidase deficiency; Pt1: Patient 1; Pt2: Patient 2; TCM: T central memory; Teff: T effector; TEM: T effector memory; TEMR: T effector memory re-expressing CD45RA; TFH: T follicular helper; Treg: T regulatory; SAA: Serum amyloid A; WISC-V: Wechsler Intelligence Scale for Children: 5th Edition.

Acknowledgements

We would like to thank Dr. Erica Schollenberg, Department of Pathology & Laboratory Medicine IWK Health Centre. We also thank the patients and their family.

Authors’ contributions

BD and NA designed the study and wrote the first draft of the manuscript. BD, NA and AH participated to the diagnostic procedures and clinical care of the patients. TI, BD, NA, SM, SR and DS were involved in the immunological analyses. TI and DS critically reviewed the manuscript. ZL performed the Ion-Exchange Chromatography. All authors contributed to the preparation of the manuscript. All authors read and approved the final manuscript.
Funding
Not applicable.

Availability of data and materials
Data are available upon request from the corresponding author.

Declarations

Ethics approval and consent to participate
The study was approved by the Nova Scotia Health Authority Research Ethics Board. All participants provided written informed consent.

Consent for publication
The patients gave consent to publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Immunology, Department of Paediatrics, Dalhousie University, IWK Health Centre, Halifax, Canada. 2 Division of Rheumatology, Department of Paediatrics, Dalhousie University, IWK Health Centre, Halifax, Canada. 3 Division of Clinical Biochemistry & Maritime Newborn Screening, Department of Pathology and Laboratory Medicine, Dalhousie University, IWK Health Centre, Halifax, Canada.

Received: 27 October 2021 Accepted: 9 February 2022 Published online: 23 February 2022

References:
1. Goodman SI, Solomons CC, Muschenheim F, McIntyre CA, Miles B, O’Brien D. A syndrome resembling lathyrism associated with iminopeptiduria. Am J Med. 1968;45(1):152–9.
2. Spodenkiewicz M, Spodenkiewicz M, Cleary M, Massier M, Fitasalos G, Cotton V, et al. Clinical genetics of prolidase deficiency: an updated review. Biology (Basel). 2020;9(5):1–18.
3. Ferreira CR, Wang H. Prolidase deficiency. In: Adam MP , Ardinger HH, Pagon RA, Wallace SE, Bean LHH, Gripp KW, Mirzazadeh A, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; pp. 1993–2022.
4. Hershkovitz T, Hassoun G, Indelman M, Shlush LI, Bergman R, Pollack S, et al. A homozygous missense mutation in PEPD encoding peptidase D causes prolidase deficiency associated with hyper-IgE syndrome. Clin Exp Dermatol. 2006;31(3):435–40.
5. Falik-Zarcar TC, Khayat M, Luder A, Frenkel P, Magen D, Brik R, et al. A broad spectrum of developmental delay in a large cohort of prolidase deficiency patients demonstrates marked interfamilial and intrafamilial phenotypic variability. Am J Med Genet. 2010;153(1):46–56.
6. Rayment JH, Jobling R, Bowdin S, Cutz E, Dell SD. Prolidase deficiency diagnosed by whole exome sequencing in a child with pulmonary capillaritis. ERU Open Res. 2019;5(2):00205–2018.
7. Bouitha A, Jeddane L, Piccard C, Al-Herz W, Alial F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUH phenotype classification. J Clin Immunol. 2020;40(1):66–81.
8. Butbul Aviel Y, Mandel H, Avitan Hersh E, Bergman R, Adiv OE, Luder A, et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE): single site experience and literature review. Pediatr Rheumatol. 2012;10(1):18.
9. Chasset F, Richez C, Martin T, Belot A, Korgonowe AS, Arnaud L. Rare diseases that mimic systemic lupus erythematosus (Lupus mimickers). Jt Bone Spine. 2019;86(2):165–71.
10. Sato S, Ohtsuka T, Tsuchiya Y, Furuchi M, Fujinaga S, Imai K, et al. Induction therapy with rituximab for lupus nephritis due to prolidase deficiency. Rheumatology. 2020;59(10):e57–9.
11. Kunier BT, D’Souza A, Bruner BF, Gross T, James JA, Targoff IN, et al. Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J Rheum Dis. 2013;16(6):674–80.
12. Costa-Reis P, Sullivan KE. Monogenic lupus: it’s all new! Curr Opin Immunol. 2017;49:87–95.
13. Dunn R, Vargos G, Winship I. A photographic essay of prolidase deficiency. Clin Dysmorphol. 2011;20(4):194–9.
14. Kunier BT, D’Souza A, Bruner BF, Gross T, James JA, Targoff IN, et al. Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J Rheum Dis. 2013;16(6):678.
15. Lupi A,Rossi A, Campari E, Pecora F, Lund AM, Elcioglu NH, et al. Molecular characterisation of six patients with prolidase deficiency: identification of the first small duplication in the prolidase gene and of a mutation generating symptomatic and asymptomatic outcomes within the same family. J Med Genet. 2006;43(12):1–7.
16. Hui K-S, Latjha A. Activation and inhibition of cerebral prolidase. J Neurochem. 1980;32(5):849–94.
17. Solak E, Kara RO, Erdem T, Mutluoglu T. A case of prolidase deficiency accompanying leg ulcers. Int J Low Extrem Wounds. 2015;14(1):92–4.
18. Freij BJ, Der Kaloustian VM. Prolidase deficiency: a metabolic disorder presenting with dermatologic signs. Int J Dermatol. 1986;25(7):431–3.
19. Wilk P, Uhlemin M, Piwowarczyk R, DobbeK H, Mueller U, Weiss MS. Structural basis for prolidase deficiency disease mechanisms. FEBS J. 2018;285(18):3422–41.
20. Beso R, Maruell S, Gioia R, Villa L, Grabowski P, Gallagher O, et al. Lack of prolidase causes a bone phenotype both in human and in mouse. Bone. 2015;72:53–64. https://doi.org/10.1016/j.bone.2014.11.009.
21. Kikuchi S, Tanoue A, Endo F, Wakuasugi S, Matsuo N, Tsujimoto G. A novel nonsense mutation of the PEPD gene in a Japanese patient with prolidase deficiency. J Hum Genet. 2000;45(2):102–4.
22. Ferreira CR, Cusmano-Ozog K. Spurious elevation of multiple urine amino acids by ion-exchange chromatography in patients with prolidase deficiency. In: Morava E, Baumgartner M, Patterson M, Rahman S, Zschocke J, Peters V, editors. JMD Reports, Volume 31. Berlin, Heidelberg: Springer; 2017. p. 45–9.
23. Pandit RA, Chen CJ, Butt TA, Islam N. Identification and analysis of a novel mutation in PEPD gene in two Kashmiri siblings with prolidase enzyme deficiency. Gene. 2013;516(2):316–6. https://doi.org/10.1016/j.gene.2012.07.070.
24. Slauenwhite D, McAlpine SM, Hanly JG, Malik A, Haifd ID, Marshall JS, et al. Association of a Type 2–Polarized T Cell Phenotype with methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheumatol. 2020;72(7):1091–102.
25. Shirinath M, Walter JH, Haeney M, Couriel JM, Lewis MA, Herrick AL. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child. 1997;76(5):441–4.
26. Cleary MA, Heaney M, Couriel JM, Walter JH. Immune function in prolidase deficiency. J Inherit Metab Dis. 1994;17(3):345–8.
27. Lubick KJ, Robertson SJ, McNally KL, Freedman BA, Rasmussen AL, Taylor RT, et al. Flavivirus antagonism of type I interferon signaling reveals prolidase as a regulator of IFNAR1 surface expression. Cell Host Microbe. 2015;18(1):61–74. https://doi.org/10.1016/j.chom.2015.06.007.
28. Ma CS, Deenick EK, Batten M, Tangey SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. 2012;209(7):1241–53.
29. Lopes I, Marques L, Neves E, Silva A, Taveira M, Pena R, et al. Prolidase deficiency with hyperimmunoglobulin E: a case report. Pediatr Allergy Immunol. 2002;13(2):140–2.
30. Cleary MA, Heaney M, Couriel JM, Walter JH. Immune function in prolidase deficiency. J Inherit Metab Dis. 1994;17(3):345–8.
31. Zschocke J, Peters V, editors. JIMD Reports, Volume 31. Berlin, Heidelberg: Springer; 2017. p. 45–9.
35. McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–6.

36. Källström E, Roscher I, Andreasson A, Bäck O, Källström E, Roscher I, et al. Decreased frequency of intracellular IFN-γ producing T cells in whole blood preparations from patients with atopic dermatitis. Exp Dermatol. 2002;11(6):556–63.

37. Alehashemi S, Goldbach-Mansky R. Human autoinflammatory diseases mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-inflammasome dysregulation update on diagnosis, treatment, and the respective roles of IL-1 and IL-18. Front Immunol. 2020;11:1840.

38. Misura M, Miltwyk W. Current understanding of the emerging role of prolidase in cellular metabolism. Int J Mol Sci. 2020;21(16):1–20.

39. Surazynski A, Miltwyk W, Palka J, Phang JM. Prolidase-dependent regulation of collagen biosynthesis. Amino Acids. 2008;35(4):731–8.

40. Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227–41.

41. Willer CJ, Schmidt EM, Sengupta S, Peluso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–85.

42. Insolia V, Priori EC, Gasperini C, Coppa F, Cocchia M, Iervasi E, et al. Prolidase enzyme is required for extracellular matrix integrity and impacts on postnatal cerebellar cortex development. J Comp Neurol. 2020;528(1):61–80.

43. Royce PM, Danks DM. Normal hydroxylation of proline in collagen synthesized by skin fibroblasts from a patient with prolidase deficiency. J Inherit Metab Dis. 1982;5(2):111–3.

44. Isazade A, Elçin G, Doğan S, Gütlerer D, Gököz D, Gürbüz B, et al. A rare cause of cutaneous ulceration: Prolidase deficiency. Int Wound J. 2019;16(4):1057–8.

45. Dunn R, Dolanitis C. Prolidase deficiency: the use of topical proline for treatment of leg ulcers. Austr J Dermatol. 2008;49(4):237–8.

46. Monafo V, Marseglia GL, Maghnie M, Dyne KM, Cetta G. Transient beneficial effect of GH replacement therapy and topical GH application on skin ulcers in a boy with prolidase deficiency. Pediatr Dermatol. 2000;17(3):227–30.

47. Karthikeyan K, Polly D, Asmathulla S, Balmurugan R, Kaviraj M. Topical proline therapy in prolidase deficiency. Clin Exp Dermatol. 2019;44(3):344–6.

48. Good AJ, Nielson CB, Schoch JJ. Topical tacrolimus therapy in the management of lower extremity ulcers due to prolidase deficiency. Pediatr Dermatol. 2019;36(6):926–8.

49. Süßmuth K, Metze D, Muresan AM, Lehmbarg K, Zur Stadt U, Speckmann C, et al. Ulceration in prolidase deficiency: successful treatment with anticoagulants. Acta Derm Venereol. 2020;100(1):10–1.

50. Olaus L, Nyárády Z. The role of platysma-based flaps in the reconstruction of massive through and through facial defects. J Plast Reconstr Aesthetic Surg. 2008;61(10):1254–6.

51. Beradesca E, Fidelì D, Bellotta M, Dyne KM, Zanaboni G, Cetta G. Blood transfusions in the therapy of a case of prolidase deficiency. Br J Dermatol. 1992;126(2):193–5.

52. Bakhitar S, Fekadu J, Seidel MG, Gambinieri E. Allogeneic hematopoietic stem cell transplantation for congenital immune dysregulatory disorders. Front Pediatr. 2019;7:461.